CA4

The CA4 gene provides instructions for making carbonic anhydrase 4, one of a family of enzymes that speed the conversion of carbon dioxide and water, which helps the body manage acid-base balance. This particular enzyme is anchored to the surface of cells lining the choriocapillaris, the network of tiny blood vessels that sits just beneath the retina. Importantly, the enzyme is not produced in the retina or in the photoreceptors (the light-sensing cells) themselves. Working together with a partner protein called NBC1, it helps move bicarbonate and keep the pH of the outer retina stable.

Changes in CA4 have been linked to an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) form of retinitis pigmentosa mapped to a region on chromosome 17 and known as RP17. Because it affects rods and later cones, the CA4-related condition has also been described as a rod-cone dystrophy. Laboratory work suggests the disease-causing versions of the enzyme fold abnormally, stress the cell's protein-processing machinery, and trigger programmed cell death in the choriocapillaris. Researchers propose that losing these blood-vessel cells reduces the retina's blood supply, and this indirect injury leads to photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) degeneration. This appears to be a toxic "gain of function" effect rather than a simple loss of the enzyme's activity.

The connection between CA4 and autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) retinitis pigmentosa is well established and is described in genetics reference resources. Across studied populations, CA4 accounts for only a small share of retinitis pigmentosa cases — on the order of 1% or less in the cohorts examined. Several specific mutations, including R14W, R69H, R219S, and A12T, have been reported in affected families and individuals. Cell-based experiments have shown that these changes disrupt how the enzyme is trafficked to the cell surface and impair its role in restoring pH after an acid load.

The precise normal function of carbonic anhydrase 4 is still not fully understood. CA4's contribution is also modest and not universal: one large screen of 200 families with autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) retinitis pigmentosa found no clearly disease-causing CA4 mutations at all. The RP17 region has become more complex to interpret, because recent work shows that many families originally grouped under RP17 carry structural rearrangements that reshape the 3D folding of the DNA and switch on a neighboring gene, GDPD1, rather than altering CA4 itself. In one report, a duplication in the RP17 region was reclassified as likely harmless after detailed functional testing, underscoring how carefully variants in this region must be interpreted.

No therapy targeting CA4 has been approved, and the supplied records do not describe an available gene-specific treatment. In laboratory cell experiments, the carbonic anhydrase inhibitor dorzolamide partly reduced the cell death caused by mutant CA4, which researchers suggested could one day be explored to ease the underlying cellular stress. This is early cell-based research only and is not evidence of a treatment for people. Separately, one study cautioned that carbonic anhydrase inhibitors, which are commonly used medications including for glaucoma, might have long-term effects on vision, making this a worthwhile topic to raise with a specialist.

• A signal-sequence mutation that triggers cell death

  Human genetic study combined with laboratory cell experiments.

  What was found:

  The mutation reduced enzyme levels and set off endoplasmic reticulum stress and apoptosis in transfected cells, suggesting a toxic mechanism rather than simple loss of function.

  Why it matters:

  It provided an early model for how CA4 changes could damage the choriocapillaris and, in turn, the retina.

  Limitation: Findings come from two families and cultured cells, not from long-term study of many patients.

• Linking pH imbalance to photoreceptor loss

  Laboratory and mechanistic study.

  What was found:

  Mutations disrupted bicarbonate transport and pH balance in the outer retina, a layer not itself expressing CA4, connecting a blood-vessel defect to photoreceptor degeneration.

  Why it matters:

  It explained why damage outside the retina can still cause retinal disease and raised a caution about carbonic anhydrase inhibitor drugs.

  Limitation: Mechanistic work does not establish how the disease unfolds or progresses in individual patients.

• How different CA4 mutations cause harm

  Laboratory cell-based study.

  What was found:

  Both impaired trafficking of the enzyme, caused endoplasmic reticulum stress and apoptosis, and their effects were partly prevented by the carbonic anhydrase inhibitor dorzolamide.

  Why it matters:

  It reinforced a shared toxic gain-of-function mechanism and pointed to a possible future research direction.

  Limitation: The protective effect was seen only in cultured cells and does not indicate an available or proven therapy.

• Rethinking the RP17 region beyond CA4

  Human genetic and laboratory mechanistic study.

  What was found:

  Complex structural variants reshaped the DNA's folding and switched on a neighboring gene, GDPD1, identified as a likely convergent disease mechanism at this locus.

  Why it matters:

  It shows that not all RP17-region disease is explained by CA4 changes, which matters for accurate diagnosis.

  Limitation: This work centers on structural variants rather than the classic CA4 missense mutations, and the two mechanisms should not be conflated.

• CA4's contribution to RP across populations

  Human genetic screening study.

  What was found:

  The mutation impaired pH recovery and, as in European patients, CA4 mutations accounted for roughly 1% or fewer of cases.

  Why it matters:

  It confirmed CA4 as a rare but real cause of RP across different populations.

  Limitation: The small number of affected individuals limits conclusions about the range of symptoms.

CA4-related retinitis pigmentosa follows an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) pattern, meaning a single altered copy can cause disease and each child of an affected parent has roughly a 50% chance of inheriting the variant. Because family members may carry the same change, relatives may wish to discuss genetic testing and counseling with their own clinicians. Beyond this inheritance point, the general guidance shown on every gene page applies.

• Is my CA4 variant classified as disease-causing, and how strong is that evidence?
• Were structural variants across the RP17 region on chromosome 17 also tested, given how often they explain this form of RP?
• Does my clinical picture fit an autosomal dominant rod-cone dystrophy, and how might it progress?
• What monitoring schedule for my vision would you recommend?
• Are there reasons for me to be cautious about carbonic anhydrase inhibitor medications, such as some glaucoma drops?
• Would testing of family members be informative given the dominant inheritance pattern?

A confirmed genetic diagnosis, ideally reviewed with a genetic counselor, can clarify whether a CA4 change is the likely cause and how confident that interpretation is. Given the interpretive complexity of the RP17 region, it may be useful to ask whether structural variants in this locus were also assessed. You can also explore studies through the RP Hope Clinical Trials Finder, which lets you begin a search with CA4 in mind.